Mar 4, 2019

Orphan drug approvals have skyrocketed under Trump

Illustration: Sarah Grillo/Axios

The past 2 years have seen a surge in the number of prescription drugs approved through a special process that was designed to help foster new treatments for rare diseases.

Why it matters: Rapid scientific advances have helped fuel this rise. But the sheer volume of rare-disease approvals is also sparking a debate about whether they're too easy to obtain, or whether they give drugmakers a way to game the system.

How it works: Federal law gives extra market protection and tax credits to "orphan" drugs — those that treat conditions affecting fewer than 200,000 people. The financial incentives are there to help offset the fact that not many people will buy these drugs.

  • The Food and Drug Administration has approved 174 drugs to treat rare diseases under the Trump administration.
  • The approval pathway has been around for 35 years, but about 23% of all orphan approvals have come in the past 2 years.

The rise of personalized medicine, especially through highly complex biologic drugs, has made it easier to target products toward specific rare conditions.

  • Treating a specific subtype of cancer, for example, is one way to win orphan status. One drug, Keytruda, received 6 orphan approvals over the past 2 years for treating different types of skin and immune-system cancers.

Yes, but: Orphan drugs are often very expensive.

  • And in many cases, orphan approvals and the accompanying financial incentives aren't being given to a newly developed drug, but rather for a new use of a product that's already on the market — including drugs that are already blockbusters.
  • In 2017, the average annual cost per patient of the top 100 orphan drugs — excluding blockbusters with additional orphan uses — was $147,308, while the average cost for the top 100 non-orphan drugs was $30,708, according to EvaluatePharma.

Go deeper

Judge declines to delay Wisconsin April 7 primary, extends absentee deadline

Photo: Darren Hauck/Getty Images

A federal judge on Thursday declined to delay Wisconsin's April 7 primary election, saying he doesn't have the authority to do so.

Why it matters: Wisconsin is the only state scheduled to vote next Tuesday that has not yet delayed its primary.

Navy removes captain of aircraft carrier who sounded alarm about coronavirus

Photo: Mai/Mai/The LIFE Images Collection via Getty Images/Getty Images

Acting Secretary of the Navy Thomas Modly relieved the captain of nuclear aircraft carrier the U.S.S. Theodore Roosevelt after he sent a letter to officials pleading for help when members of his crew contracted the coronavirus.

The big picture: Capt. Brett Crozier's four-page letter was leaked to the San Francisco Chronicle earlier this week, quickly garnering national attention after Crozier pleaded for more resources and more space to quarantine crew members offshore. Modly said at a press conference that Crozier went outside the chain of command and "at no time relayed" the levels of alarm that he wrote in his letter.

Go deeperArrow17 mins ago - Health

The coronavirus unemployment numbers in perspective

Data: U.S. Department of Labor; Chart: Danielle Alberti/Axios

Over the past two weeks, 10 million Americans have filed for unemployment, with millions more to come.

Why it matters: The jobless hits right now are like a natural disaster hitting every state at the same time.